Table 1 Demographic and clinical data of the study group
Parameter | Result |
|---|---|
Age (Yrs): mean ± SD | 56.00 ± 8.22 |
Gender | |
Male, n (%) | 78/100 (78%) |
Female, n (%) | 22/100 (22%) |
BMI(Kg/m2): mean ± SD | 24.76 ± 3.48 |
Risk factors & comorbidities | |
DM, n (%) | 56/100 (56%) |
Hypertension, n (%) | 70/100 (70%) |
Renal impairment, n (%) | 18/100 (18%) |
Dyslipidemia, n (%) | 68/100 (68%) |
Smoking, n (%) | 62/100 (13%) |
Alcoholic, n (%) | 2/100 (2%) |
OSA, n (%) | 11/100 (11%) |
Drug treatment | |
β Blockers, n (%) | 100/100 (100%) |
Loop diuretics, n (%) | 88/100 (88%) |
MRAs, n (%) | 98/100 (98%) |
SGLT2 inhibitor, n (%) | 100/100 (100%) |
Empagliflozin | 19/100 (19%) |
Dapagliflozin | 81/100 (81%) |
NYHA class | |
I, n (%) | 13/100 (13%) |
II, n (%) | 55/100 (55%) |
III, n (%) | 32/100 (32%) |
IV, n (%) | 0 |
Echo parameters | |
LV EF (%) | 31.59 ± 5.68 |
LVEDD (cm) | 6.38 ± 0.62 |
LVESD (cm) | 5.00 ± 0.83 |
LAD (cm) | 4.59 ± 0.56 |
DD (≥ II grade)% | 63/100 (63%) |
Mitral regurgitation (MR) (≥ II grade) % | 60/100 (60%) |
ECG parameters | |
Heart rate (beats per minute) | 78.14 ± 9.98 |
Atrial fibrillation (%) | 23/100 (23%) |
PR interval (ms) | 138.53 ± 26.72 |
QRS width (ms) | 123.70 ± 20.32 |
QTc interval (ms) | 425.37 ± 32.86 |
T wave morphology changes (%) | 74/100 (74%) |
ST segment changes (%) | 60/100 (60%) |
QRS width | |
Wide ≥ 120 ms | 69 (69%) |
Narrow < 120 ms | 13 (13%) |
QRS morphology (in patients with wide QRS width) | |
LBBB | 25 (25%) |
RBBB | 17 (17%) |
IVCD | 27 (27%) |